Using micro data on virtually all of the drugs and diseases of over 500,000 people enrolled in Puerto Rico's Medicaid … program, we examine the impact of the vintage (original FDA approval year) of drugs used to treat a patient on the patient's 3 … services, and the nature and complexity of illness. We find that people using newer drugs during January-June 2000 were less …

hypothesis the hypothesis that newer drugs increase the length and quality of life and estimate the rate of progress. To do this … primarily from the 1997 Medical Expenditure Panel Survey. We find that people who used newer drugs had better post …-treatment health than people using older drugs for the same condition, controlling for pre-treatment health, age, sex, race, marital …

of the developing world introduces patent protection for new drug products. This may lead to more research on drugs to … might enhance, or dampen, a firm's responsiveness to the availability of product patents. The picture presented here …

common rationale for patents. For external effects, this analogy has the important and unrecognized implication that classic …

producing better products under new patents. Therefore, one may divide up the source of competition facing an innovator into … from production of products on other patents. Previous theoretical and empirical micro -based analyses have emphasized the … competition between-patents through so called therapeutic competition. We estimate that between-patent competition, most of which …

Pharmaceutical firms' use of secondary patents to extend periods of exclusivity generates concerns among policymakers … worldwide. In response, some developing countries have introduced measures to curb the grant of these patents. While these … countries with restrictions on secondary patents, India, Brazil, and Argentina. We examine cross-country comparisons of primary …